Published online Oct 27, 2024. doi: 10.4254/wjh.v16.i10.1208
Revised: September 24, 2024
Accepted: October 11, 2024
Published online: October 27, 2024
Processing time: 102 Days and 21.5 Hours
In this letter, we comment on a recent publication by Mei et al, in the World Journal of Hepatology, investigating the hepatoprotective effects of the modified Xiaoyao San (MXS) formula in a male rat model of non-alcoholic steatohepatitis (NASH). The authors found that MXS treatment mitigated hepatic steatosis and inflammation in the NASH model, as evidenced by the reduction in lipid droplets (LDs), fibrosis markers and lipogenic factors. Interestingly, these hepatoprotective effects were associated with androgen upregulation (based on metabolomics analysis of male steroid hormone metabolites), adenosine 5’-monophosphate-activated protein kinase (AMPK) activation, and restoration of phosphatase and tensin homolog (PTEN) expression. However, the authors did not clearly discuss the relationships between MXS-induced hepatic steatosis reduction in the NASH model, and androgen upregulation, AMPK activation, and restoration of PTEN expression. This editorial emphasizes the reported mechanisms and explains how they act or interact with each other to reduce hepatic steatosis and inflammation in the NASH model. As a perspective, we propose additional mechanisms (such as autophagy/lipophagy activation in hepatocytes) for the clearance of LDs and suppression of hepatic steatosis by MXS in the NASH model. A proper understanding of the mechanisms of MXS-induced reduction of hepatic steatosis might help in the treatment of NASH and related diseases.
Core Tip: Modified Xiaoyao San (MXS) formula has hepato-protective effects in a male rat model of non-alcoholic steatohepatitis (NASH) via suppression of steatosis and inflammation. These protective effects are related to several mechanisms, including the regulation of sex hormone metabolism, androgen upregulation, adenosine 5’-monophosphate-activated protein kinase activation, and enhanced phosphatase and tensin homolog expression. A deeper understanding of the mechanisms behind MXS-induced reduction of hepatic steatosis could assist in the treatment of NASH and related diseases.